Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +7.50p +3.30% 235.00p 230.00p 240.00p 235.00p 227.50p 227.50p 9,622 08:37:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -17.2 -45.2 - 75

ReNeuron Group plc Total Voting Rights

03/06/2019 7:00am

UK Regulatory (RNS & others)


Reneuron (LSE:RENE)
Historical Stock Chart

2 Months : From May 2019 to Jul 2019

Click Here for more Reneuron Charts.

TIDMRENE

RNS Number : 8479A

ReNeuron Group plc

03 June 2019

 
 3 June 2019   AIM: RENE 
 

ReNeuron Group plc

Total Voting Rights

At 31 May 2019, the Company had 31,801,617 ordinary shares in issue, all with voting rights. The Company holds no ordinary shares in treasury. The above figure of 31,801,617 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

ENDS

ENQUIRIES:

 
ReNeuron                                         +44 (0)20 3819 8400 
Olav Hellebø, Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                         +44 (0) 20 7466 5000 
Mark Court, Sophie Wills, Tilly Abraham 
 
Stifel Nicolaus Europe Limited                   +44 (0) 20 7710 7600 
Jonathan Senior, Stewart Wallace, Ben Maddison 
 (NOMAD and Joint Broker) 
N+1 Singer                                       +44 (0) 20 7496 3000 
Aubrey Powell, Mark Taylor (Joint Broker) 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRDMGGVLZLGLZM

(END) Dow Jones Newswires

June 03, 2019 02:00 ET (06:00 GMT)

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190723 11:09:23